BioTuesdays

Author - Leonard Zehr

Catalyst
Markets

Rodman starts Catalyst Biosciences at buy

Rodman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday. Using its proprietary protease platform...

June 30, 2016
OpGen Logo
Markets

Rodman starts OpGen at buy

Rodman & Renshaw has initiated coverage of OpGen (NASDAQ:OPGN) with a “buy” rating and 12-month price target of $2.50. The stock closed at $1.56 on Tuesday. “In our view, the company’s QuickFISH assays, the latest...

June 29, 2016
Vascular Biogenics
Markets

HCW starts Vascular Biogenics at buy

H.C. Wainwright has launched coverage of Vascular Biogenics (NASDAQ:VBLT) with a “buy” rating and 12-month price target of $11. The stock closed at $4.10 on Tuesday. Vascular Biologics, also known as VBL Therapeutics or...

June 29, 2016
NeuroMetrix
Markets

Rodman starts NeuroMetrix at buy

Rodman & Renshaw has initiated coverage of NeuroMetrix (NASDAQ:NURO) with a “buy” rating and 12-month price target of $4.50. The stock closed at $1.74 on Tuesday. NeuroMetrix is a commercial-stage medical device...

June 29, 2016
oramed
Developments

OrbiMed joins Round B NovellusDx financing

OrbiMed will join a $10-million financing round by closely-held NovellusDx led by IntraCure, a public life science holding company, and Pontifax, a leading Israeli life sciences VC, raising the size of the round to $12...

June 21, 2016